[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100358755":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":35,"centralContacts":40,"locations":50,"responsibleParty":68,"collaborators":70,"id":73,"slug":74,"hasResults":75,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":26,"eligibilityCriteria":79,"healthyVolunteers":80,"sex":81,"minAge":82,"maxAge":83,"enrollmentInfo":84,"targetDuration":45,"studyType":87,"phases":88,"briefSummary":91,"conditions":92,"keywords":45,"overallStatus":53,"whyStopped":45,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":105},{"fullName":5,"class":6},"Genesis Athens Clinic","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Participants receiving PRP treatment","EXPERIMENTAL","Perimenopausal women, 40-50 years of age, treated with autologous PRP intra ovarian infusion.",[13],"Biological: Autologous Platelet Rich Plasma (PRP) intra ovarian infusion",{"label":15,"type":16,"description":11,"interventionNames":17},"Participants receiving Platelet Free Plasma (PFP)","PLACEBO_COMPARATOR",[18],"Other: Placebo: Autologous Platelet Free Plasma (PFP) intra ovarian infusion",[20,28],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"BIOLOGICAL","Autologous Platelet Rich Plasma (PRP) intra ovarian infusion","Autologous PRP intra ovarian infusion",[9],[26,27],"PRP","Platelet Rich Plasma",{"type":6,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"Placebo: Autologous Platelet Free Plasma (PFP) intra ovarian infusion","Autologous PFP intra ovarian infusion",[15],[33,34],"PFP","Platelet Free Plasma",[36],{"name":37,"affiliation":38,"role":39},"Agni Pantou, MD","Obstetrician Gynecologist","STUDY_DIRECTOR",[41,47],{"name":42,"role":43,"phone":44,"phoneExt":45,"email":46},"Mara Simopoulou, PhD","CONTACT","+306979234100",null,"marasimopoulou@hotmail.com",{"name":48,"role":43,"phone":45,"phoneExt":45,"email":49},"Agni Pantou, MD, PhD Candidate","agni.pantou@genesisathens.gr",[51],{"facility":52,"status":53,"city":54,"state":45,"zip":55,"country":56,"countryCode":57,"cosmosGeoPoint":58,"geoPoint":63,"contacts":64},"Genesis AC","RECRUITING","Athens","15232","Greece","GR",{"type":59,"coordinates":60},"Point",[61,62],23.72784,37.98376,{"lat":62,"lon":61},[65,66],{"name":48,"role":43,"phone":45,"phoneExt":45,"email":49},{"name":67,"role":43,"phone":45,"phoneExt":45,"email":45},"Konstantinos Pantos, MD,PhD",{"type":69,"investigatorFullName":45,"investigatorTitle":45,"investigatorAffiliation":45,"oldNameTitle":45,"oldOrganization":45},"SPONSOR",[71],{"name":72,"class":6},"National and Kapodistrian University of Athens","100358755","phase-2-autologous-platelet-rich-plasma-prp-intra-ovarian-infusion-in-perimenopausal-women-100358755",false,"NCT03951194","Autologous Platelet Rich Plasma (PRP) Intra Ovarian Infusion in Perimenopausal Women","Investigating Improvement of Ovarian Function Following Autologous PRP Intra-ovarian Infusion in Perimenopausal Women","Inclusion Criteria:\n\n* Women ≥40 years of age, presenting with cycle irregularities while fulfilling at least one of the respective two criteria: more than seven days difference in menstrual cycle duration between two consecutive cycles OR, presence of a menstrual cycle duration over sixty days and progressive elevation of FSH levels.\n* Discontinuation of any complementary\u002Fadjuvant treatment including hormone replacement, acupuncture, and botanotherapy, for at least three months prior to recruitment.\n* Willing to comply with study requirements\n\nExclusion Criteria:\n\n* Any pathological disorder related to reproductive system anatomy\n* Amenorrhea\n* Endometriosis\n* Adenomyosis\n* Fibroids and adhesions\n* Infections in reproductive system\n* Current or previous diagnosis of cancer in reproductive system\n* History of familiar cancer in reproductive system\n* Severe male factor infertility\n* Prior referral for PGT\n* Ovarian inaccessibility\n* Previous POI diagnosis -Endocrinological disorders (Hypothalamus-\n* Pituitary disorders, thyroid dysfunction, diabetes mellitus, metabolic syndrome)\n* BMI\\>30 kg\u002Fm2 or BMI\\\u003C18.5 kg\u002Fm2\n* Systematic autoimmune disorders",true,"FEMALE","40 Years","50 Years",{"count":85,"type":86},100,"ESTIMATED","INTERVENTIONAL",[89,90],"PHASE2","PHASE3","Autologous PRP intra ovarian infusion may improve ovarian response and women's hormonal profile and may promote folliculogenesis in perimenopausal women.",[93,94,95],"Infertility, Female","Perimenopausal Disorder","Menstrual Cycle Abnormal","2026-07-05",{"date":98,"type":99},"2026-07-08","ACTUAL",{"date":101,"type":99},"2019-06-13",{"date":103,"type":86},"2028-07-30",{"name":5,"class":6},1]